Literature DB >> 30080925

Should human germ line editing be allowed? Some suggestions on the basis of the existing regulatory framework.

Iñigo de Miguel Beriain1,2.   

Abstract

The application of genetic editing techniques for the prevention or cure of disease is a highly promising tool for the future of humanity. However, its implementation contains a number of ethical and legal challenges that should not be underestimated. On this basis, some sectors have already asked for a veto on any intervention that modifies the human germ line, while supporting somatic line editing. In this paper, I will support that this suggestion makes no sense at all, because the somatic/germ line disjunctive has no moral relevance and, therefore, it should not play any role in legal terms. I will provide a number of reasons to hold this assumption, such as the non-sacred nature of the germ line, the difference between germ line and human genome modification, or the moral importance of the presence of a will to create modified descendants. While doing so, I will provide some examples of the different approaches to germ line editing adopted by different regulations so as to demonstrate that, contrary to what is sometimes stated, a general ban on this practice is not the rule, but the exception. Additionally, I will show how alternative options which currently exist, such as a selective ban based on criteria different to the germ line/somatic line distinction, match better with the need to conciliate research needs and legitimate ethical concerns. Finally, I will introduce some further suggestions to this same purpose.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  gene editing ethics; gene editing regulation; germ line protection; germ line therapy ethics; human genome ethics

Mesh:

Year:  2018        PMID: 30080925     DOI: 10.1111/bioe.12492

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  2 in total

1.  Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy.

Authors:  Sebastian Schleidgen; Hans-Georg Dederer; Susan Sgodda; Stefan Cravcisin; Luca Lüneburg; Tobias Cantz; Thomas Heinemann
Journal:  BMC Med Ethics       Date:  2020-09-11       Impact factor: 2.652

2.  The Promise of CRISPR for Human Germline Editing and the Perils of "Playing God".

Authors:  Larry G Locke
Journal:  CRISPR J       Date:  2020-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.